GMGalina Marder

Galina Marder

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Galina Marder has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Real-world experience with obinutuzumab in difficult-to-treat myositis: concise report of a case series

    by Ivana Ilic, Sonali Narain, Galina Marder

    Objectives: Idiopathic inflammatory myopathy (IIM) is an orphan systemic disorder with muscular, cutaneous and pulmonary involvement. B cell–directed therapies, including rituximab, belimumab and chimeric antigen receptor T-cell (CAR-T), have shown promise in altering disease outcome. We report the benefit of obinutuzumab in difficult -to- treat myositis patients. Methods: The Northwell Rheumatology database was searched for obinutuzumab-treated patients (2019–24); five of them met 2017 EULAR/ACR classification criteria for IIM and were included in the analysis. Demographic, clinical, serological and imaging data were collected. Overall response was rated as complete, partial or no response based on clinical response and physician global assessment. Total improvement score was not calculated because data were collected retrospectively. Descriptive statistics were used for analyses. Results: Of five patients, two had antisynthetase syndrome, one dermatomyositis (DM) and two overlap myositis. Most patients failed at least three immunosuppressive agents. The reason for obinutuzumab use was rituximab allergy and worsening of interstitial lung disease (ILD) and myositis activity (3/5), arthritis (2/5) and severe rash (1/5 patients), despite rituximab. After obinutuzumab 80% of patients had overall improvement by 3–6 months. Respiratory status improved/stabilized in all ILD patients. Two patients required second obinutuzumab cycle: one for recurrence and another for persistent disease with B cell re-population. One was lost to follow-up after the second cycle and was deemed a non-responder. At last observation, 4/5 patients had achieved a complete response. No hypogammaglobulinaemia, significant infections or hospitalizations were observed. Conclusion: Obinutuzumab was safe and provided durable improvement in difficult-to-treat myositis patients with rituximab allergy, further highlighting targeting the B-cell pathway.

  • Abatacept for the treatment of myositis-associated interstitial lung disease

    by Rohit Aggarwal, Nantakarn Pongtarakulpanit, Daniel I Sullivan, Siamak Moghadam-Kia, Sangmee Sharon Bae, Jesse Wilkerson, Didem Saygin, Galina Marder, Swamy Venuturupalli, Paul F Dellaripa, et al.

    Objectives: This randomized, placebo-controlled pilot trial evaluated the efficacy and safety of abatacept in patients with anti-synthetase syndrome-associated interstitial lung disease (ASyS-ILD). Methods: Participants with active ASyS-ILD were randomized to receive abatacept (n = 9) or placebo (n = 11) for 24 weeks, followed by a 24-week open-label extension with abatacept for all participants. The primary endpoint was a change in % predicted forced vital capacity (%FVC) from baseline to week 24. Secondary endpoints included changes in the FVC (ml), % predicted diffusing capacity of the lung for carbon monoxide (%DLCO), shortness of breath questionnaire (SOBQ) and pulmonary disease activity on a visual analogue scale (VAS) at weeks 24 and 48. Pre-post baseline analysis of FVC and quantitative image analysis (QIA) of high-resolution computed tomographic scans were performed. Data were analysed using a generalized linear mixed model. The study was not powered for primary or secondary endpoints. Results: At week 24, there was no significant difference in the primary endpoint of %FVC change between abatacept and placebo (between treatment difference of −0.35, 95%CI −6.91 to 6.21, P = 0.914) and in all secondary endpoints. However, by week 48, trends favouring abatacept in %FVC, FVC (ml), %DLCO and SOBQ were observed without statistical significance. There was a significant improvement in pulmonary disease activity VAS and pre-post baseline slopes of %FVC and QIA scores in the abatacept arm. Abatacept was generally well tolerated. Conclusion: Abatacept did not significantly improve %FVC at 24 weeks. However, trends at 48 weeks suggest potential benefits, supporting the need for a larger, long-term randomized controlled trial. Clinical trial registration: clinicaltrials.gov; NCT03215927


  • Open Access

    Relationship between high-resolution computed tomography quantitative imaging analysis and physiological and clinical features in antisynthetase syndrome-related interstitial lung disease

    by Sangmee Sharon Bae, Fereidoun Abtin, Grace Kim, Daniela Markovic, Cato Chan, Siamak Moghadam-Kia, Chester V Oddis, Daniel Sullivan, Galina Marder, Swamy Venuturupalli, et al.

    Objectives: To explore the association between the extent of CT abnormalities by quantitative imaging analysis (QIA) and clinical/physiological disease parameters in patients with antisynthetase syndrome associated interstitial lung disease (ARS-ILD). Methods: We analysed 20 patients with antisynthetase antibodies and active ILD enrolled in the Abatacept in Myositis-Associated Interstitial Lung Disease study. High-resolution chest CT was obtained at weeks 0, 24 and 48 and QIA scored the extent of ground glass (quantitative score for ground glass), fibrosis (quantitative score for lung fibrosis, QLF) and total ILD (quantitative ILD, QILD). Mixed-effects models estimated longitudinal QIA scores over time. Associations between QIA scores with clinical/physiological parameters were analysed longitudinally using repeated-measures mixed-effects models. Results: Patients were median age 57 years, 55% males and 85% white. Higher (worse) baseline QIA scores correlated with lower baseline forced vital capacity (FVC) and diffusing capacity adjusted for haemoglobin (DLCO). Longitudinal QIA trajectories trended towards improving scores during the trial, and patients on O2 at baseline had worsening QIA trajectories which were different from patients who were not on O2. Longitudinal QIA scores demonstrated strong associations with both FVC and DLCO over time. Higher QILD scores over time were also associated with worse dyspnoea scores, pulmonary visual analogue scale, physician and patient global disease activity, health status in 6/8 domains of the Short Form-36 and higher oxygen requirements. Patients with significant radiographic improvement at 48 weeks had higher baseline QLF, QILD and worse DLCO. Conclusions: Longitudinal QIA scores associate with lung physiology, patient perception of respiratory status, overall disease activity and quality of life over time in ARS-ILD. QIA may allow reproducible monitoring of disease progression and response to therapy over time. Trial registration number: NCT03215927.


  • Associations between 6-minute walk distance and physiologic measures and clinical outcomes in myositis-associated interstitial lung disease

    by Sangmee Sharon Bae, Daniela Markovic, Didem Saygin, Daniel Sullivan, Koichi Yamaguchi, Siamak Moghadam-Kia, Chester V Oddis, Fereidoun Abtin, Grace Hyun J Kim, Galina Marder, et al.

    Objective: The 6-min walk test (6MWT) is a simple test widely used to assess sub-maximal exercise capacity in chronic respiratory diseases. We explored the relationship of 6-min walk distance (6MWD) with measurements of physiological, clinical, radiographic measures in patients with myositis-associated interstitial lung disease (MA-ILD). Method: We analysed data from the Abatacept in Myositis Associated Interstitial Lung Disease (Attack My-ILD) study, a 48-week multicentre randomized trial of patients with anti-synthetase antibodies and active MA-ILD. 6MWD, forced vital capacity (FVC), diffusing capacity (DLCO), high-resolution CT and various physician-/patient-reported outcome measures were obtained during the trial. Spearman’s correlations and repeated-measures analysis with linear mixed-effects models were used to estimate the associations between 6MWD and various physiologic, clinical and radiographic parameters both cross-sectionally and longitudinally. Results: Twenty participants with a median age of 57 years, 55% male and 85% white were analysed. Baseline 6MWD did not associate with baseline pulmonary function tests. Repeated-measures analysis showed 6MWD over time associated with FVC over time, but not with DLCO. 6MWD over time also correlated with University of California San Diego Shortness of Breath questionnaire dyspnoea score, Borg scores, as well as global disease activity and muscle strength over time. Emotional role functioning, vitality, general health and physical functioning scores by Short Form 36 also correlated with 6MWD over time. Conclusions: Exploratory work in a small cohort of MA-ILD demonstrated 6MWD over time associated with parallel changes in FVC and patient-reported outcomes of dyspnoea, but not with DLCO. Larger studies are needed to validate the reliability, responsiveness and utility of the 6MWT in MA-ILD. Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT03215927.


  • Open Access

    Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases

    by Erik Anderson, Michael Powell, Emily Yang, Ananya Kar, Tung Ming Leung, Cristina Sison, Rebecca Steinberg, Raven Mims, Ananya Choudhury, Carlo Espinosa, et al.

    Patients with autoimmune diseases are at higher risk for severe infection due to their underlying disease and immunosuppressive treatments. In this real-world observational study of 463 patients with autoimmune diseases, we examined risk factors for poor B and T cell responses to SARS-CoV-2 vaccination. We show a high frequency of inadequate anti–spike IgG responses to vaccination and boosting in the autoimmune population but minimal suppression of T cell responses. Low IgG responses in B cell–depleted patients with multiple sclerosis (MS) were associated with higher CD8 T cell responses. By contrast, patients taking mycophenolate mofetil (MMF) exhibited concordant suppression of B and T cell responses. Treatments with highest risk for low anti–spike IgG response included B cell depletion within the last year, fingolimod, and combination treatment with MMF and belimumab. Our data show that the mRNA-1273 (Moderna) vaccine is the most effective vaccine in the autoimmune population. There was minimal induction of either disease flares or autoantibodies by vaccination and no significant effect of preexisting anti–type I IFN antibodies on either vaccine response or breakthrough infections. The low frequency of breakthrough infections and lack of SARS-CoV-2–related deaths suggest that T cell immunity contributes to protection in autoimmune disease.


  • Belimumab treatment of adult idiopathic inflammatory myopathy

    by Galina Marder, Tam Quach, Priyal Chadha, Preeya Nandkumar, Jimmy Tsang, Todd Levine, Elena Schiopu, Richard Furie, Anne Davidson, Sonali Narain

    To evaluate belimumab addition to standard of care (SoC) in patents with refractory Idiopathic Inflammatory Myopathy (IIM). We conducted a 40-week multicentre randomized, double-blind, placebo-controlled trial with 1:1 IV belimumab 10 mg/kg or placebo randomization and a 24-week open-label extension. Clinical responses were measured by the Definition of Improvement (DOI) and Total Improvement Score (TIS). Flow cytometry analyses were performed on available samples before randomization, at 24 and 60–64wk. Descriptive statistics, t test, Fisher’s exact test and ANOVA tests were used. 17 patients were randomized, 15 received ≥ 5 doses of belimumab or placebo and were included in the intention -to-treat analysis. More belimumab patients vs placebo attained TIS ≥ 40 (55.5% vs 33.3%; p=NS) and achieved DOI (33.3% vs 16.7%; p = NS) at Wk40 and Wk64; mean TIS was similar among groups. Two patients achieved major responses (TIS= 72.5) after Wk40 in the belimumab arm, none in the placebo arm. No improvement in placebo arm after switching to the open label phase was observed. There was no steroid-sparing effect. No new safety signals were detected. Although total B-cells were not reduced, belimumab induced naïve B-cells depletion while enhancing memory B cells number and frequency. The study did not meet the primary end point and no statistically significant differences were observed in clinical responses between arms. More patients achieved sustained TIS ≥ 40 and reached DOI. Most patients who received belimumab longer than 40 weeks had clinical improvement. Phenotypic changes in B cell populations were not associated with clinical responses. Clinicaltrials.gov, https://clinicaltrials.gov/, NCT02347891


  • Open Access

    Comparative Survival Analysis of Immunomodulatory Therapy for COVID-19 ‘Cytokine Storm’: A Retrospective Observational Cohort Study

    by Sonali Narain, Dimitre G. Stefanov, Alice S. Chau, Andrew G. Weber, Galina S Marder, Blanka Kaplan, Prashant Malhotra, Ona Bloom, Audrey Liu, Martin L. Lesser, et al.

    Background: Cytokine storm is a marker of COVID-19 illness severity and increased mortality. Immunomodulatory treatments have been repurposed to improve mortality outcomes. Methods: We conducted a retrospective analysis of electronic health records across the Northwell Health system. COVID-19 patients hospitalized between March 1, 2020 and April 15, 2020, were included. Cytokine storm was defined by inflammatory markers: ferritin >700ng/mL, C-reactive protein >30mg/dL, or lactate dehydrogenase >300U/L. Patients were subdivided into six groups -no immunomodulatory treatment (standard of care) and five groups that received either corticosteroids, anti-interleukin 6 (IL-6) antibody (tocilizumab) or anti-IL-1 therapy (anakinra) alone or in combination with corticosteroids. The primary outcome was hospital mortality. Results: There were 3,098 patients who met inclusion criteria. The most common comorbidities were hypertension (40-56%), diabetes (32-43%) and cardiovascular disease (2-15%). Patients most frequently met criteria with high lactate dehydrogenase (74.8%) alone, or in combination, followed by ferritin (71.4%) and C-reactive protein (9.4%). More than 80% of patients had an elevated D-dimer. Patients treated with a combination of tocilizumab and corticosteroids (Hazard Ratio [HR]: 0.459, 95% Confidence Interval [CI]: 0.295-0.714; p<0.0001) or corticosteroids alone (HR: 0.696, 95% CI: 0.512-0.946; p=0.01) had improved hospital survival compared to standard of care. Corticosteroids and tocilizumab was associated with increased survival when compared to corticosteroids and anakinra (HR: 0.612, 95% CI: 0.391-0.958; p-value=0.02). Conclusions: When compared to standard of care, corticosteroid and tocilizumab used in combination, or corticosteroids alone, was associated with reduced hospital mortality for patients with COVID-19 cytokine storm.


  • The Musculoskeletal System in Systemic Lupus Erythematosus

    by Diane Horowitz, Galina Marder, Richard Furie